CoViproteHCt
- Duration
- 18/4/2020 - 31/12/2021
- Coordinator
- Technische Universität München
- Funded by
- EIT Health
The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. A significant gap is the lack of test systems to identify people already immune to SARS-CoV-2 and who would thus be protected from re-infection. While development of numerous serological assays is underway worldwide, it remains unknown whether the measured immune responses are truly protective. CoViproteHCt addresses this gap by rapidly developing and validating such urgently needed assays to characterize protective immune responses that can then be used to identify protected individuals, in particular healthcare personnel (HCP) working with COVID-19 patients and in other critical areas. The developed assays can subsequently be adapted by companies and academic partners throughout the world within weeks.
This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.
Funding
678.671 €
Our Team
Our Team
-
Carlota Dobaño Research Professor
-
Alberto García-Basteiro Associate Research Professor
-
Alfredo Mayor Research Professor
-
Gemma Moncunill Assistant Research Professor
Other projects
See Past ProjectsCOMBACTE
Combating Bacterial Resistance In Europe
GAMA
Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting
Evaluation of Strategies for Yaws Eradication
Yaws eradication
Novel Marine Biomolecules against Biofilm (NoMorFilm)
Application to medical devices
COMBACTE-CARE
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
MAMAH
Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women
INTE-AFRICA
Integrating and decentralizing diabetes and hypertension services in Africa
ICARIA
Improving Care through Azithromycin Research for Infants in Africa
PreFIT
Predicting the Future: Incipient Tuberculosis
Predicting the Future: Incipient Tuberculosis
Encuesta serológica Cendea de Cizur
Cendea de Cizur
Projecte de Recerca en Resposta Immunitària i Epidemiologia de Malalties Infeccioses
Conèixer la propagació. Entendre la protecció
ANTICOV
Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19
Stool4TB
Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV
TB-RECONNECT
Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status
SToolNIH
Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring
ALIA - Las ciudades y la salud
Planificación urbana, medio ambiente y salud | Clima y salud | Resistencias Antimicrobianas
END-VOC
ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)
TwinAir
Digital Twins Enabled Indoor Air Quality Management for Healthy Living
Estudio de la propagación de bacterias y genes de resistencia a los antibióticos en el ciclo integral del agua, en el área metropolitana de Barcelona
Propagación de la resistencia en aguas
Nuevos complejos de oro (III) frente a bacterias multirresistentes
Project Code: DTS21/00004
Desarrollo de dos nuevas estrategias terapéuticas (inhibidores de bombas de expulsion y ARN antisentido) activos frente a bacterias mutliresistentes
Más allá de la supresión vírica del VIH: un cuarto noventa para mejorar la salud de personas viviendo con el VIH en España
Project Code: PI20/01654
ENDÈMIC
Community knowledge generation through scientific culture, urban ecology and art
EpiGen
Building Scalable Pathogen Genomic Epidemiology in Ethiopia
Hepatitis C Free Baleares
Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.
FLAVOBAC
Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias